Login

Repros Announces the Issuance of New US Patent

20-Apr-2017|Source : AG-IP News|Visits : 2452

THE WOODLANDS, Texas - Repros Therapeutics Inc.® announced in a press release the issuance of a new patent, US Patent number 9,616,074 (the ‘074 patent), that bolsters the Company's intellectual property relating to Proellex® (telapristone acetate). The ‘074 patent, which expires in 2027, relates to the use of Selective Progesterone Receptor Modulators (SPRM), in particular Telapristone Acetate (Proellex®) or Ulipristal Acetate, with an Off Drug Interval (ODI) for the treatment of estrogen-dependent hyperproliferative uterine conditions, such as uterine fibroids and endometriosis. Under the terms of the patent, ODI is defined as daily administration of the SPRM for a period of time, followed by an ODI sufficient for the patient to menstruate and then by another period of administration of the SPRM.

Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.